Myasthenia Gravis - Market Insight, Epidemiology and Market Forecast 2027
Myasthenia Gravis (MG) is an autoimmune syndrome caused by the failure of neuromuscular transmission, which results from the binding of autoantibodies to proteins involved in signaling at the neuromuscular junction (NMJ). These proteins include the nicotinic Acetyl Cholinesterase (AChR) or, less frequently, a muscle-specific tyrosine kinase (MuSK). Clinically, MG has 2 major subtypes, primary ocular and generalized. MG often progresses to the more severe and generalized form with weakness of the head, neck, trunk, limb and respiratory muscles. The condition...
View full press release